Clarivate Epidemiology’s coverage of dermatitis comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of dermatitis for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.
Clarivate Epidemiology’s dermatitis forecast will answer the following questions:
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of dermatitis over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Clarivate Epidemiology forecasts the following dermatitis patient population:
Total 12-Month Prevalence of Dermatitis per 100 People of All Ages in 2020 and 2030
Relative Sizes of the Contributing Factors to the Trend in Total 12-Month Prevalent Cases of Dermatitis Over the Next 10 Years
Total 12-Month Prevalent Cases of Dermatitis
Studies Included in the Analysis of Dermatitis
Studies Excluded from the Analysis of Dermatitis
Risk/Protective Factors for Dermatitis
Misba Farooq, M.P.H.,is an associate epidemiologist at Clarivate. Previously, she worked as a hospital-based physiotherapist. She received her M.P.H. from the Tata Institute of Social Sciences and has a bachelor’s degree in physiotherapy.
Nishant Kumar, M.P.H.
Nishant Kumar, M.P.H., is a senior director on the Epidemiology team at Clarivate. His areas of expertise are oncology and CNS diseases, including Alzheimer’s disease and dementia. His key interests in oncology are modeling disease progression and drug-treatable incident and prevalent populations. Previously, Mr. Kumar sized patient populations for rare and niche diseases, such as graft-versus-host disease and Duchenne muscular dystrophy. He earned his M.P.H. with a concentration in epidemiology and statistics from King’s College in London and a B.Sc. (Honors) in medical studies from the University of Birmingham.